GNLX - NASDAQ

Genelux Corporation

GNLX·NASDAQ

$3.05

+2.7%

HealthcareBiotechnology

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$114.73M

EPS-0.8600

P/E Ratio-3.55

Earnings Date08/06/2026

gnlx

Common Stock

Last Annual Value

38.00K

3-Year CAGR

62%

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Genelux Corporation Competitors Analysis of Common Stock

GNLX · NASDAQ

Company	Common Stock	CAGR 3Y	CAGR 5Y	CAGR 10Y
Genelux Corporation NASDAQ:GNLX	38.00K	12.1%	33.4%	N/A
Aldeyra Therapeutics, Inc. NASDAQ:ALDX	60.16K	0.5%	0.7%	16.9%
Codexis, Inc. NASDAQ:CDXS	9.00K	8.7%	8.4%	8.4%
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP	2.00K	N/A	-30.7%	-7.7%
Invivyd, Inc. NASDAQ:IVVD	28.00K	36.5%	20.5%	N/A
OmniAb, Inc. NASDAQ:OABI	14.00K	5.3%	N/A	N/A
Pyxis Oncology, Inc. NASDAQ:PYXS	63.00K	11.9%	14.5%	N/A
SELLAS Life Sciences Group, Inc. NASDAQ:SLS	15.00K	71.0%	49.6%	0.0%
Candel Therapeutics, Inc. NASDAQ:CADL	550.00K	23.8%	14.0%	N/A
Lexeo Therapeutics, Inc. Common Stock NASDAQ:LXEO	7.00K	32.6%	33.1%	N/A
Contineum Therapeutics, Inc. Class A Common Stock NASDAQ:CTNM	37.00K	164.5%	25.3%	N/A

Genelux Corporation Fair Value Envelope

GNLX · NASDAQ

Our analysis suggests that GNLX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.05, this represents a potential HIDDEN relative to our calculated worth for Genelux Corporation.

HIDDEN

Intrinsic Value

Current Price: $3.05

Related Guides

Blog Categories

Continue your GNLX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.